Research antibodies act as vital tools in laboratory techniques such as western blotting etc. that are conducted for research purposes. Due to their high specificity and sensitivity, antibodies and associated reagents make an important tool that aids in the detection of molecules and its analysis, which allows researchers to draw conclusions related to drug target, disease occurrence, and immune system pathways. Research antibodies are essential detecting techniques used by scientists. When attempting to understand why a cell function has gone wrong, antibodies can be used to mark and identify specific proteins that are present in the diseased cell at a specific stage of the disease life cycle.
Global Research Antibodies Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 610 million cases and 6.51 million deaths due to coronavirus (COVID-19) were reported till September 22, 2022, across the globe.
Impact of COVID-19 on Demand and Supply of Research Antibodies
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
However, Coronavirus (COVID-19) pandemic is expected to positively impact growth of the global research antibodies market during the forecast period. For instance, in February, 2022, U.S. Food and Drug Administration (FDA), granted an emergency use authorization (EUA) of novel monoclonal antibody against the omicron variant for the treatment of COVID-19. EUA was authorized for mild to moderate COVID-19 in adults and children (12 years of age and older) who weigh at least 40 kilograms (88 pounds) and patients who have a positive COVID-19 test.
Global research antibodies market is estimated to be valued at US$ 3,574.6 Mn in 2022, and is expected to exhibit a CAGR 5.9% over the forecast period (2022-2030).
Figure 1: Global Research Antibodies Market Share (%) Analysis, By Product Type, 2022
Increasing research and development activities related to research antibodies are expected to drive the growth of market over the forecast period.
Increasing research and development activities related to research antibodies are expected to fuel growth of the global research antibodies market over the forecast period. For instance, according to a research article published in the journal eLife, non-profit, open access, scientific journal for the biomedical and life sciences, in March 2022, the study was conducted by researchers at the University of Washington, the Max Planck Institute for Dynamics and Self-Organization, and the University of Cologne on broadly neutralizing antibodies, or bNAbs (Broadly Neutralizing Antibodies) and it was observed that bNAbs could be used to treat HIV (Human Immunodeficiency Virus) while reducing the risk of the spreading virus. The study demonstrates that computational methods for selecting combinations of bNAbs based on viral genetics will help prevent viral escape, increasing the efficacy of HIV treatment.
Increasing product launches and approvals by market players are expected to drive growth of the global research antibodies market over forecast period.
Market players are engaged in product approvals, which is expected to boost the global research antibodies market growth over the forecast period. For instance, on January 21, 2020, Horizon Therapeutics plc, a biopharmaceutical company focused on researching, developing, and commercializing medicines, received the U.S. FDA (Food and Drug Administration) approval for the Tepezza (TM) (teprotumumab-trbw), therapeutic monoclonal antibody for the Treatment of Thyroid Eye Disease (TED). TED is a severe, progressive, and eyesight-threatening uncommon autoimmune condition that is accompanied by proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation, and facial disfigurement. Tepezza is the first and only medication for TED to get the U.S. FDA (Food and Drug Administration) approval.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 3,574.6 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 5.9% | 2030 Value Projection: | US$ 5,637.8 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals, Abcam plc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Restraint- Global Research Antibodies Market
Challenges associated with storage conditions of antibodies is expected to hamper the growth of global research antibodies market over forecast period, challenges include –
Global Research Antibodies Market – Regional Analysis
On the basis of region, the global research antibodies market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to be the most lucrative region in the global research antibodies market, owing to increasing cases of lung cancer in the U.S. For instance, according to Centers of Disease Control and Prevention, in 2019, 221,097 new cases of lung and bronchus cancer were reported, and 139,601 people died of this cancer in the U.S.
Europe is expected to witness significant growth in the forecast period, owing to increasing approvals for monoclonal antibodies for the treatment of diseases. For instance, in December 2021, Vir Biotechnology, Inc., U.S.-based Biotechnology Company and GlaxoSmithKline plc. a British multinational pharmaceutical and biotechnology company announced that the European Commission (EC) approved Xevudy (sotrovimab) for commercialization for the early treatment of COVID-19. Sotrovimab is now approved in the European Union (EU) for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and are at elevated risk of advancing to severe COVID-19 (aged 12 years and above and weighing at least 40kg).
Figure 2: Global Research Antibodies Market Value (US$ Mn), by Region, 2022
Global Research Antibodies Market – Competitive Landscape
Major players operating in the global research antibodies market include Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina and Phoenix Pharmaceuticals.
The small proteins known as antibodies, which are an essential component of immune system's reaction to diseases, are helpful in biomedical research. For decades, researchers have been developing antibodies to fight and understand viruses like Covid-19 and many common infectious disorders. The majority of antibodies used in research are referred to as "animal-derived" and are obtained from animals. A small quantity of the desired foreign antigen is injected into an animal. This triggers the immune system to generate antibodies in defense. These are then collected for use in research, either from the spleen or the blood.
Market Dynamics
Increasing collaborations and partnerships in market players is expected to witness significant growth in forecast period. For instance, in March 2022, Sanofi, a French multinational pharmaceutical and healthcare company and Seagen Inc., an American biotechnology company announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Sanofi is now working on an ADC, which is an antibody designed to carry powerful anti-cancer medications to tumor cells expressing a certain protein.
Increasing product launches by market players are expected to drive growth of the global research antibodies market over the forecast period. For instance, in April 2019, ImmunoPrecise, a full-service, therapeutic antibody discovery company launched DeepDisplay, Antibody Discovery Platform with an unknown U.S. based Pharma Company. In contrast to conventional technologies, DeepDisplay uses a transgenic animal immunization combined with phage display antibody selection to deliver the most therapeutically-relevant antibodies in the shortest amount of time with the highest chances of success.
Increasing product approvals are expected to drive growth of market over the forecast period. For instance, in April 2021, Gilead Sciences Inc., an American biopharmaceutical company announced that Trodelvy (sacituzumab govitecan-hziy), for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, has received full approval from the U.S. Food and Drug Administration (FDA). Trodelvy (sacituzumab govitecan-hziy) is an antibody–drug conjugate that combines a humanized monoclonal antibody.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients